Hormones therapy for management of menopausal breast cancer risk

Minerva Ginecologica

Volumn 64, Issue 3, 2012, Pages 223-230

  Files, J A ^a   Allen, S V ^b   Pruthi, S ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Breast neoplasms; Hormone replacement therapy; Hot flashes; Menopause; Quality of life; Signs and symptoms; Survivor

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIETHYLSTILBESTROL; ESTRADIOL; ESTRIOL; ESTROGEN RECEPTOR; GESTAGEN; TIBOLONE;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN THERAPY; EVIDENCE BASED PRACTICE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; PREVALENCE; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; RISK FACTORS;

EID: 84864378621     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Piscitelli P, Santoriello A, Buonaguro FM, Di Maio M, Iolascon G, Gimigliano F et al. Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. J Exp Clin Cancer Res 2009;28:86.
2. D'Alo D, Stracci F, Cassetti T, Scheibel M, Pascucci C, La Rosa F. Recent trends in incidence, mortality and survival after cancer of the female breast and reproductive organs. Umbria, Italy: 1978-2005. Eur J Gynaecol Oncol 2010;31:174-80.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
4. Miller B, Kolonel L, Bernstein L, Young JJ, Swanson G, West D et al. Racial/Ethnic Patterns of Cancer in the United States 1988-1992. Bethesda, MD: National Cancer Institute; 1996.
5. National Cancer Institute. SEER Stats Fact Sheet: Breast 2010 [Internet]. Available from: http://seer.cancer.gov/statfacts/html/breast.html [cited 2012 Feb 1]
6. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S et al. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements 2009;26:1-27.
7. Pruthi S, Gostout BS, Lindor NM. Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc 2010;85:1111-20.
8. Casey PM, Cerhan JR, Pruthi S. Oral contraceptive use and risk of breast cancer. Mayo Clinic Proc 2008;83:86-90.
9. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87:1681-5.
10. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85. (Pubitemid 32108534)
11. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:907-22.
12. Marier V. Early twentieth-century Canadian medical patent law in practice: James Bertram Collip and the discovery of Emmenin. Univ Toronto Law J 2010;60:855-92.
13. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005;118(Suppl 12B):64-73.
14. Seaman B. The Greatest experiment ever performed on women: Exploding the Estrogen Myth. New York: Hyperion; 2003.
15. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-7.
16. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-70.
17. Gambrell RD, Jr. Prevention of endometrial cancer with progestogens. Maturitas 1986;8:159-68.
18. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53. (Pubitemid 38040534)
19. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
20. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-87.
21. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92.
22. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12. (Pubitemid 38489892)
23. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. AmJ Epidemiol 2008;167:1407-15.
24. Beral V, Reeves G, Bull D, Green J, Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011;103:296-305.
25. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. (Pubitemid 36999703)
26. Col NF, Kim JA, Chlebowski RT. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 2005;7:R535-40.
27. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-82.
28. Stahlberg C, Pedersen AT, Lynge E, Ottesen B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand 2003;82:335-44. (Pubitemid 36570717)
29. von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005;97:533-5. (Pubitemid 40590435)
30. Stahlberg C, Pederson AT, Lynge E, Ottesen B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand 2003;82:335-44. (Pubitemid 36570717)
31. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65-73.
32. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135-46.
33. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11-33.
34. Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004;11:519-30. (Pubitemid 40362150)
35. Boon HS, Olatunde F, Zick SM. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 2007;7:4.
36. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-13-
37. Loprinzi CL, Barton DL, Sloan JA, Novotny PJ, Dakhil SR, Verdirame JD et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause 2008;15:655-60.
38. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63. (Pubitemid 32009821)
39. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-71. (Pubitemid 44794007)
40. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J et al. Hormone therapy and the risk of breast cancer in BRCAl mutation carriers. J Natl Cancer Inst 2008;100:1361-7.
41. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-83. (Pubitemid 47517552)
42. Ibe C, Simon JA. Vulvovaginal atrophy: current and future therapies (CME). J Sex Med 2010;7:1042-50; quiz 51.
43. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009;12:91-105.
44. Pruthi S, Simon JA, Early AP. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 2011;17:403-8.
45. National Institutes of Health. Serum estradiol levels in postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors and vaginal estrogen [Internet]. ClinicalTrials.gov Identifier: NCT00984399. Available at: http://clinicaltrials.gov/ct2/show/NCT00984399 [cited 2012, Feb 1].
46. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923-31.
47. National Institutes of Health. Vaginal testosterone cream for atrophic vaginitis in women taking aromatase inhibitors for breast cancer. ClinicalTrials. gov Identifier: NCTOl 122342 [Internet]. Available at: http://clinicaltrials.gov/ct2/show/NCT01122342 [cited 2012 Feb 1].
48. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A et al. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-84. (Pubitemid 44707921)
49. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol 1997;388:507-25. (Pubitemid 27481288)
50. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-95. (Pubitemid 28138739)
51. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001;344:1207-13-
52. Ganz PA, Castellon SA, Silverman DH. Estrogen, tamoxifen, and the brain. J Natl Cancer Inst 2002;94:547-9. (Pubitemid 34498638)
53. Maki Y, Ura C, Yamaguchi T, Murai T, Isahai M, Kaiho A et al. Effects of intervention using a community-based walking program for prevention of mental decline: a randomized controlled trial. J Am Geriatr Soc 2012 [Epub ahead of print].